• 1
    Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: KoopmanWJ, editor. Arthritis and allied conditions. 14th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001. p. 1590624.
  • 2
    Rodnan GP, Jablonska S, Medsger TA Jr. Classification and nomenclature of progressive systemic sclerosis. Clin Rheum Dis 1979; 5: 513.
  • 3
    Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982; 33: 167240.
  • 4
    Okano Y, Medsger TA Jr. Antibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1990; 33: 18228.
  • 5
    Okano Y, Steen VD, Medsger TA Jr. Antibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993; 119: 100513.
  • 6
    Reimer G, Steen VD, Penning CA, Medsger TA Jr, Tan EM. Correlates between autoantibodies to nucleolar antigens and clinical features in patients with systemic sclerosis (scleroderma). Arthritis Rheum 1988; 31: 52532.
  • 7
    Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 14859.
  • 8
    Targoff IN, Reichlin M. Nucleolar localization of the PM-Scl antigens. Arthritis Rheum 1985; 28: 22630.
  • 9
    Treadwell EL, Alspaugh MA, Wolfe JF, Sharp GC. Clinical relevance of PM-1 antibody and physiochemical characterization of PM-1 antigen. J Rheumatol 1984; 11: 65862.
  • 10
    Okano Y, Steen VD, Medsger TA Jr. Autoantibody to U3 nucleolar ribonucleoprotein (fibrillarin) in patients with systemic sclerosis. Arthritis Rheum 1992; 35: 95100.
  • 11
    Clements PJ, Lachenbruch PA, Seibold JR, Zee B, Steen VD, Brennan P, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. J Rheumatol 1993; 20: 18926.
  • 12
    Hardin JA, Rahn DR, Shen C, Lerner MR, Wolin SL, Rossa MD, et al. Antibodies from patients with connective diseases bind specific subsets of cellular RNA-protein particles. J Clin Invest 1982; 70: 1417.
  • 13
    Reddy R, Tan EM, Henning D, Nogha K, Bush H. Detection of a nucleolar 7-2 ribonucleoprotein and cytoplasmic 8-2 ribonucleoprotein with autoantibodies from patients with scleroderma. J Biol Chem 1983; 258: 13836.
  • 14
    Hashimoto C, Steitz JA. Sequential association of nucleolar 7-2 RNA with two different autoantigens. J Biol Chem 1983; 258: 137982.
  • 15
    Gold HA, Craft J, Hardin JA, Bartkiewicz M, Altman S. Antibodies in human serum that precipitate ribonuclease P. Proc Natl Acad Sci U S A 1988; 85: 54837.
  • 16
    Gold HA, Topper JN, Clayton DA, Craft J. The RNA processing enzyme RNase MRP is identical to the Th RNP and related to RNase P. Science 1989; 245: 137780.
  • 17
    Jiang T, Altman S. Protein-protein interactions with subunits of human nuclear RNase P. Proc Natl Acad Sci U S A 2001; 98: 9205.
  • 18
    Yamane K, Ihn H, Kubo M, Kawana M, Asano Y, Yazawa N, et al. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma. Rheumatology 2001; 40: 6836.
  • 19
    Steen VD, Powell DL, Medsger TA Jr. Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis. Arthritis Rheum 1988; 31: 196203.
  • 20
    MacGregor A, Canavan R, Knight C, Denton C, Davar J, Coghlan J, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology (Oxford) 2000; 40: 4539.
  • 21
    Gunduz OH, Fertig N, Lucas M, Medsger TA Jr. Systemic sclerosis with renal crisis and pulmonary hypertension. Arthritis Rheum 2001; 44: 16636.
  • 22
    Kuwana M, Kaburaki J, Okano Y, Tojo T, Homma M. Clinical and prognostic associations based on serum antinuclear antibodies in Japanese patients with systemic sclerosis. Arthritis Rheum 1994; 37: 7581.
  • 23
    Higuchi M, Horiuchi T, Ishibashi N, Yoshizawa S, Niho Y, Nagasawa K. Anticentromere antibody as a risk factor for cancer in patients with systemic sclerosis. Clin Rheumatol 2000; 19: 1236.
  • 24
    Masi AT, Rodnan GP, Medsger TA Jr, Altman R, D'Angelo W, Fries J, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 58190.
  • 25
    Medsger TA Jr. Comments on Scleroderma Criteria Cooperative Study. In: Current topics in rheumatology: systemic sclerosis (scleroderma). BlackCM, MyersAR, editors. New York: Gower Medical Publishing; 1985. p. 167.
  • 26
    Scussel-Lonzetti L, Joyal F, Raynauld J-P, Roussin A, Goulet J-R, Rich E, et al. Are the ACR systemic sclerosis classification criteria useful for diagnosis? [abstract] Arthritis Rheum 2000; 43: S315.